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Background: The objective of this study was to investigate whether an anti-spasticity medication can facilitate the
effects of robotic locomotor treadmill training (LTT) to improve gait function in people with incomplete spinal cord
injury (SCI).
Methods: Individuals with chronic incomplete SCI were recruited and carried out a 4 week intervention of either
locomotor treadmill training (LTT) alone (n = 26) or LTT combined with Tizanidine (TizLTT), an anti-spasticity medication
(n = 22). Gait function was evaluated using clinical outcome measures of gait, speed and endurance. To better
understand the underlying mechanisms of the therapeutic effects, maximal strength, active range of motion
(AROM) and peak velocity (Vp) of ankle dorsi- and planter-flexor muscles were also measured. Differences were
assessed using two-way mixed design analysis of variance. The number of subjects that achieved the minimal
important difference (MID) for clinical scores was also measured for each group, and the results of those that did
attain the MID were compared with those that did not.
Results: Both LTT and TizLTT resulted in significant improvements in walking speed and dorsiflexion maximum
strength, with no significant differences between them, using group-averaging analysis. However, using the MID
analysis, a higher proportion of subjects in the TizLTT group achieved the MID for walking speed (40%) compared
with LTT alone (13%). Those that achieved the MID for walking speed were significantly higher functioning at
baseline than those that did not in the TizLTT group, and the change in walking speed was associated with the
change in dorsiflexion peak velocity (R2 = 0.40; P < 0.05).
Conclusion: Tizanidine appears to facilitate the effects of LTT on gait function in individuals with chronic SCI that
are higher functioning at baseline. We speculate that this may be due to restoration of inhibitory mechanisms by
Tizanidine, resulting in greater stretch in the planterflexor muscles during the LTT.
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An incomplete spinal cord injury (SCI) results in the
partial loss of motor and sensory function below the level
of the injury. Therefore affected individuals retain func-
tional ability to varying degrees. SCI rehabilitation aims
to optimize functional recovery after incomplete SCI.
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unless otherwise stated.abnormalities resulting in hypertonia of muscle groups,
which are thought to be the result of a combination
of intrinsic and reflex-mediated muscle stiffness [1].
Spasticity, defined as a velocity-dependent resistance
to stretch (reflex-mediated hypertonia), is associated
with substantially increased muscle activity (measured
by electromyography (EMG)) during stretch compared
with healthy subjects under passive conditions [2,3], which
may be due to reduced inhibitory mechanisms in chronic
SCI subjects [4,5].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the ankle joint, which have important roles during func-
tional tasks [6]; however the relationship between hyper-
tonia and gait function remains controversial. It has been
suggested that the reduced inhibitory mechanisms observed
in spastic muscles under passive conditions do not further
decrease during voluntary contractions [7]. In healthy sub-
jects inhibitory mechanisms do decrease from passive to
voluntary conditions, resulting in similar levels of inhibition
during voluntary contractions between healthy people and
patients with spasticity [7]. In support, clinical indications
of spasticity (measured in the passive muscle) have been
proposed to be unrelated to gait impairment, as evidenced
by preserved timing of muscle activation during spastic gait
in stroke and SCI patients [7,8]. Additionally, based on clin-
ical observations, reduced hypertonia was not associated
with improved function [9,10]. Conversely, our earlier study
noted increased reflex stiffness in SCI compared with
healthy subjects under active conditions [11] and other
studies have demonstrated that increased hypertonia relates
to impaired function [12,13].
Tizanidine, an anti-spasticity medication, has been shown
to reduce hypertonia in SCI individuals, evidenced by a
reduction in passive resistance [14-17]. As an α2 norad-
renergic agonist, it is thought to reduce hypertonia through
depression of dorsal horn interneuron excitability [18],
thereby reducing reflex-mediated hypertonia (spasticity).
The effects of Tizanidine on functional outcomes have sel-
dom been studied [19], thus the effects of Tizanidine on
gait impairment remain ambiguous. It has been reported
that Tizanidine significantly improved voluntary activation
(muscle activity) [15] and substantially reduced reflex
mechanical responses [20] in SCI individuals. In addition,
Tizanidine has been shown to facilitate locomotor capacity
in spinalized cats [21]. Thus Tizanidine may improve gait
function through several mechanisms including restored
inhibitory mechanisms and improved voluntary activation.
A popular tool intended to optimize recovery of gait
function specifically after SCI is locomotor treadmill
training (LTT) [22], which may incorporate body-weight
supported and/or robotic-assistive gait training. Previous
studies have reported improvements in overground
walking speed [23] [24] and endurance [23] after LTT
in people with chronic SCI. LTT has also been reported to
reduce abnormal neuromuscular activity, measured by
clinical scores [25], EMG activity [26,27], or neuromuscu-
lar mechanical properties [28], although these changes did
not correlate with functional improvements [25]. A recent
review article however suggested that the evidence for
LTT is limited [29] since studies often omit alternative
intervention groups, and those that do include alternative
interventions have found similar improvements from con-
ventional physical therapy and overground walking train-
ing compared with LTT [24,30,31].Recently therefore, combination therapies have been
proposed in an attempt to surpass the outcomes of single
interventions [32]. Some evidence in support of this
theory comes from combined functional electrical stimu-
lation (FES) and LTT studies, which have noted improved
gait quality when using combined FES + LTT and FES +
overground walking therapies than robotic locomotor
training [24] or regular physical therapy [33] provided
alone. In SCI patients, the potential for functional im-
provements from LTT may be limited by prevailing spasti-
city. We recently demonstrated that Tizanidine improved
walking speed and endurance in some patients that were
higher functioning [34]. Tizanidine may have allowed
greater voluntary activation and/or range of motion at the
ankle joint and may therefore facilitate LTT resulting in
greater improvements in both walking speed and endur-
ance. The combined effects of anti-spasticity medication
and LTT in people with incomplete SCI have seldom been
investigated. One study found improvements in walking
speed and endurance in two case studies; these individuals
were taking baclofen, as part of their usual care, during an
intervention of LTT. These individuals were in the acute
phase of injury and there was no control comparison,
therefore the facilitatory effects of the anti-spasticity
medication could not be separated from that of the LTT
and spontaneous recovery [35]. The facilitatory effects
of Tizanidine on LTT have not previously been reported,
except in our interim conference reports [36-38].
Importantly, the population of people living long-term
with chronic incomplete SCI is heterogeneous in terms
of functional levels, and the previously reported extents
and rates of improvement in functional performance from
interventions are variable [29]. We recently demonstrated
that group averaging techniques can therefore mask im-
portant data. We reported that both Tizanidine and LTT
interventions resulted in improvements in walking speed
and endurance, with no difference between interventions.
However, we further analyzed the data of individuals that
achieved improvements greater than the minimal import-
ant difference (MID) for a given clinical test, and noted
that Tizanidine administered alone was more beneficial
for higher functioning individuals. Therefore, MID analysis
should be employed alongside group-averaging techniques
to further explore the effects of interventions, in such
heterogeneous populations.
This study aimed to address two questions: i) can Tiza-
nidine combined with LTT improve clinical gait scores in
people with incomplete SCI to a greater extent than LTT
alone and ii) if Tizanidine does facilitate LTT, what are the
underlying mechanisms. We used a combination of ana-
lysis techniques, including group averaging and MID to
answer these questions. We hypothesized that LTT would
improve walking speed when administered alone, and
that Tizanidine would facilitate LTT in higher functioning
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speed compared with LTT alone. In order to explore the
underlying mechanisms associated with functional out-
comes, we investigated the effects of LTT alone and Tiza-
nidine combined with LTT on muscle strength of ankle
plantar- and dorsi-flexor muscles, active range of motion
and peak movement velocity of dorsiflexors.Methods
Subjects with either cervical or thoracic incomplete spinal
cord injury, as a result of trauma, were recruited from
the outpatient service at the Rehabilitation Institute of
Chicago. All subjects provided written informed consent
and the study had ethical approval from the Northwestern
University Institutional Review Board. Inclusion criteria
were aged >18 years, motor incomplete SCI (ASIA Im-
pairment Scale [AIS] classification C or D) with level of
injury above T10 and >12 months post injury, ambulatory
or potentially ambulatory, medical clearance to partici-
pate, evidence of clinical spasticity in the muscles sur-
rounding the ankle and knee joints (Modified Ashworth
Score (MAS) ≥1), and lower-limb passive range of mo-
tion within functional limits for ambulation. Exclusion
criteria were sitting tolerance <2 hours, existing infection,
severe cardiovascular or pulmonary disease, concomitant
neurological injury, history of fractures post-SCI, and
known orthopedic or peripheral nerve injury in the lower
extremities.
Subjects were randomly assigned into one of two inter-
vention groups; LTT alone (LTT; n = 26) or combined
LTT and Tizanidine (TizLTT; n = 22). Subjects assigned to
the TizLTT group, were initially provided with Tizanidine
alone for a period of 4 weeks, and results for that period
have been presented elsewhere, together with the LTT
group clinical outcomes [34]. Twenty seven subjects in
total were recruited into the TizLTT group, however
only 22 subjects continued to the combined treatment.
Subject characteristics for the two groups are provided
in Table 1.Table 1 Mean (SD) characteristics of subjects in the LTT
alone (LTT) and combined LTT and Tizanidine (TizLTT)
groups
LTT (n = 26) TizLTT (n = 22)
Gender 7 F; 19 M 7 F; 15 M
Age (years) 46.6 (12.6) 46.5 (11.9)
Time since injury (years) 9.3 (8.9) 10.2 (10.4)
Level of injury 20 C; 6 T 13 C; 9 T
WISCI II score 14.7 (5.2) 15.2 (5.1)
F = Female; M =Male; C = Cervical; T = Thoracic; WISCII II = Walking Index for
Spinal Cord Injury II.Interventions
Locomotor training was provided using a robot-assisted
locomotor training device (Lokomat, Hocoma AG,
Switzerland). This device provides body-weight sup-
ported gait assistance such that the individual is sus-
pended in a harness over a motorized treadmill while the
frame of the robot, attached by straps to the outside of the
lower limbs, moves the limbs in a natural walking pattern.
Training was provided three times per week for four
weeks; each session lasted ≤1 hour, with 30–45 minutes
of training. Treadmill speed, body-weight support, and
robotic guidance forces were determined by the physical
therapist, based on tolerance and comfort of the subject.
Generally however, reducing guidance force was prioritized
to promote voluntary drive to muscles, and to minimize
passive training. Participants were encouraged to con-
tribute to the gait training as much as possible and to
increase gait speed. Body-weight support was config-
ured to maximize lower-extremity loading without pro-
ducing excessive knee flexion during the stance phase,
or allowing toe-drag during the swing phase. Subjects
were instructed to “walk with the robot” to ensure that
the lower-extremity movements were consistent with the
Lokomat stepping pattern. Subjects were also instructed
to pay attention to their ankle movements during the gait
cycle i.e. to focus on planting the heel of their foot at heel-
strike and to “lift their toes” during the swing phase. A
mirror placed in front of the subjects provided visual
feedback.
For the TizLTT group, .03 mg/kg of Tizanidine was
administered four times a day for eight weeks (with LTT
provided during the final 4 weeks). This dosage repre-
sents a useful compromise, in that it usually shows effi-
cacy [20], but does not cause overwhelming side effects.
In the first week, administration of the drug was pro-
gressively increased until the full dosage was received on
day 7, and the full dosage was then administered for a
subsequent 8-week period. Subjects taking muscle re-
laxant medications prior to enrolling on the study were
tapered from their medication prior to the start of the
study.
Outcome measures
Outcomes were measured at 0, 1, 2 and 4 weeks from
the start of LTT for both groups. Outcome measures were:
i) the Timed up and go (TUG) whereby subjects are
instructed to stand up from an armed chair, walk 3
meters, turn, return to the chair and sit down; ii) the 10-
meter walk test (10MWT) performed at the fastest speed,
whereby subjects are instructed to walk 10 meters as
quickly and safely as possible and; iii) the 6-minute walk
test (6MWT) whereby subjects are instructed to walk for
6 minutes and the distance covered is measured. Func-
tional measures were chosen to evaluate different aspects
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ing speed and endurance, respectively.
For voluntary activation measures, subjects were seated
in a custom-built isokinetic dynamometer. The ankle of
their most spastic side (assessed by the MAS) was strapped
to a footplate, which was attached to the rotational axis of
a servomotor, and their knee was fixed at an angle of 150°.
Ankle joint angular position and torque were measured by
a rotary encoder and a 6-axis torque transducer, respect-
ively. Data were sampled at 1 kHz by a 16 bit A/D con-
verter, and anti-alias filtered on-line at 200 Hz. Subjects
were instructed to push down and pull up with their
foot “as hard and as fast as possible” to assess maximal
isometric muscle strength of plantar- and dorsi-flexor
muscles, respectively, with the ankle fixed at an angle
of 90° (maximum voluntary isometric contractions; MVIC).
Subjects also carried out maximal isokinetic voluntary con-
tractions by rotating the foot from maximum plantarflexion
to maximum dorsiflexion (when the motor was deactivated)
to assess active range of motion (AROM) and peak
isokinetic velocity (Vp). Isometric and isokinetic tests
were both repeated twice; the MVIC with the highest
plateau force (isometric) and the trial with the highest
ROM (isokinetic) were used for analysis.
Data analysis
Maximal isometric torque during both plantar- and dorsi-
flexion MVICs was measured as the average torque
over the 3-second period in which the torque standard
deviation was lowest. For isokinetic contractions, Vp was
measured as described previously [39]. Briefly, the onset
of the task was defined as the first sample with an acceler-
ation >5% peak acceleration. The end of the task was
defined as the final sample with an acceleration >5% peak
acceleration. AROM was taken as the difference between
the angular position of the ankle at the onset and end of
the task (as defined above). Vp was taken as the peak mea-
sured velocity between the onset and end of the task.
Independent t-tests were used to compare subject char-
acteristics and baseline clinical scores between groups.
Fisher’s exact tests were used to compare the gender and
injury level (cervical vs thoracic) distribution between
groups. Two way mixed design analysis of variance
(ANOVA) was used to identify significant changes due to
time-point (within-subject) and group (between-subject).
MID values were calculated using the formula proposed
by Beckerman et al. [40] (1.96*√2*SEM) based on our pre-
viously presented control data. The MID values were
0.11 m/s, 37.1 m, and −14.5 s for the 10MWT, 6MWT
and TUG, respectively [34]. The number of subjects that
achieved these MID values were calculated. In order to
determine the characteristics of the subjects that achieved
the MID, WISCI II and baseline scores for each measure
were compared between those that did and did not achievethe MID, using independent t-tests. Finally, changes in
MVIC torque, AROM and peak movement velocity were
compared using two way ANOVAs to better understand
the underling mechanisms of the change in those that did
achieve the MID. An alpha value <0.05 was considered
significant.
Results
There was no significant difference in age, time since injury
and WISCI II scores between the two groups (p > 0.05;
Table 1). The distribution of males:females and level of
injury (cervical:thoracic) were also not significantly differ-
ent between groups (p > 0.05; Table 1). Baseline scores for
walking speed (10MWT), endurance (6MWT) and TUG
were not significantly different between groups (p > 0.05).
Group averaging analysis (ANOVA)
Walking speed improved significantly with time for both
groups (p < 0.001) with no difference between groups
(Figure 1a). There were no significant changes with time
for the TUG and 6MWT (Figure 1b-c). There was a
small but significant increase in maximum dorsiflexion
torque after 4 weeks due to LTT or TizLTT (p < 0.05),
with no significant difference between groups (Table 2).
There were no significant changes in plantarflexion maximal
torque, AROM and Vp with time and between groups
(Table 2).
MID analysis
The number of subjects that achieved the MID for each
clinical test in both groups is shown in Figure 2a-c. For
the 6MWT and TUG, only 2–3 subjects achieved the
MID, irrespective of intervention group. However, for
the 10MWT, 8 subjects (40%) in the combined TizLTT
group had achieved the MID after 4 weeks of training,
compared with only 3 subjects (13%) in the LTT alone
group (Figure 2). The subjects that achieved the MID
for walking speed were higher functioning individuals
at baseline in the TizLTT group (Table 3), evidenced
by significantly higher WISCI II scores (p < 0.01), and
significantly improved baseline scores for the 10MWT
(p = 0.02), 6MWT (p = 0.02) and TUG (p = 0.01). Subjects
that achieved the MID for walking speed in the LTT alone
group were not higher functioning compared with those
that did not, when assessed by WISCI II scores (p > 0.05),
however their baseline scores for walking speed (p = 0.01)
and endurance (p = 0.02) were significantly higher among
the subjects that achieved the MID for walking speed.
Baseline MVIC, AROM and Vp did not differ between
those that did and did not attain the MID for walking
speed in both groups (Table 3). These findings in the
LTT group should be interpreted with caution due to
the low number of subjects that did achieve the MID
for walking speed (n = 3).
bc
0.40
0.50
0.60
0.70
0.80
S
pe
ed
 (
m
/s
)
** ++
100
150
200
250
D
is
ta
nc
e 
(m
)
20
30
40
50
60
T
im
e 
(s
)
Time (weeks)
** +
(a)
(b)
(c)
0 1 2 3 4
Figure 1 Mean (SEM) walking (a) speed from 10 minute walk test, (b) distance from the 6-minute walk test and c) time from the timed
up and go test for the locomotor treadmill training (LTT; blue) and LTT combined with Tizanidine (TizLTT; red) groups. **p < 0.001
compared with baseline and +p < 0.003 and ++p < 0.001 compared with Week 2.
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tween the subjects that did and did not achieve the
MID, based on the 10MWT only, since the number of
subjects that achieved the MID was too low in other
groups to make meaningful conclusions. Changes in
MVIC, AROM and Vp with time did not differ betweenTable 2 Mean (SEM) maximum voluntary isometric contractio
active range of motion (AROM) and peak movement velocity
combined with Tizanidine (TizLTT) groups at 0, 1, 2 and 4 we
MVIC PF (Nm) MVIC DF (Nm)
LTT TizLTT LTT TizLTT
Week 0 28.1 (4.4) 30.8 (4.5) 12.3 (1.4) 11.5 (1.7)
Week 1 26.2 (3.4) 33.8 (5.8) 12.2 (1.4) 12.0 (2.0)
Week 2 27.6 (3.9) 33.9 (6.6) 12.0 (1.4) 12.1 (2.0)
Week 4 28.4 (4.1) 33.7 (5.6) 13.2* (1.7) 13.0* (2.1
*Denotes significant difference compared with 0, 1 and 2 weeks (p < 0.05).the subjects that did and did not achieve the MID for
walking speed among both intervention groups, however
Vp tended to increase in the subjects that achieved the
MID within the TizLTT group compared with those that
did not attain the MID, and all subjects in the LTT alone
group (Figure 3a). There was also a significant moderaten (MVIC) plantarflexion (PF) and dorsiflexion (DF) torque,
(Vp) for locomotor treadmill training alone (LTT) and LTT
eks after the start of LTT
AROM (°) Vp (°/s)
LTT TizLTT LTT TizLTT
34.1 (3.3) 45.1 (7.5) 117.1 (13.5) 165.1 (26.2)
37.1 (3.1) 48.7 (7.3) 130.7 (14.1) 182.6 (26.8)
36.3 (3.4) 46.6 (7.2) 126.8 (14.6) 179.6 (27.4)
) 35.6 (3.1) 49.2 (7.4) 121.5 (13.6) 186.9 (28.1)
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Figure 2 Change in clinical scores at 4 weeks from baseline for the (a) 10 meter walk test, (b) 6 minute walk test and (c) timed up and
go, for subjects in the locomotor treadmill training (LTT; blue) and LTT combined with Tizanidine (TizLTT; red) groups. Dashed lines
denote the minimal important difference (MID) for each test [34].
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change in Vp among the TizLTT group (R2 = 0.40, p < 0.05;
Figure 3b).
Discussion
This study measured the facilitatory effects of Tizanidine,
an anti-spasticity medication, on LTT in people with
chronic SCI. We have noted that both LTT alone and LTT
combined with Tizanidine significantly improved walking
speed and maximum dorsiflexion torque. The number ofTable 3 Mean (SEM) baseline clinical scores and baseline kine
locomotor treadmill training and Tizanidine (TizLTT) and loco
did not achieve the minimal important difference (MID) for w
Group TizLTT
Test MID achieved MID not achieved
WISCI II score 18.9 (0.9) 14.3 (1.1)
10MWT speed (m/s) 0.8 (0.1) 0.4 (0.1)
6MWT distance (m) 280.5 (30.8) 154.6 (35.8)
TUG time (s) 15.0 (1.9) 51.8 (12.5)
MVIC torque PF 30.7 (6.3) 30.9 (6.7)
DF 11.4 (2.2) 11.7 (2.9)
AROM 54.2 (15.2) 40.2 (8.3)
Vp 189.4 (42.5) 151.9 (34.0)
Walking index for spinal cord injury II (WISCI II); 10 meter walk test (10MWT); 6 min
contraction (MVIC); plantarflexors (PF); dorsiflexors (DF); active range of motion (AROsubjects that achieved the MID was highest among the
TizLTT group, with 40% of individuals achieving the
MID for walking speed. Among that group, the subjects
that achieved the MID were significantly higher func-
tioning, and changes may relate to improvements in
dorsiflexion peak velocity. These findings indicate that
Tizanidine can facilitate the locomotor training in
people with SCI that are higher functioning, perhaps by
improved ankle dorsiflexion through reduced spasticity
in plantarflexors.tic and kinematic variables for subjects in the combined
motor treadmill training alone (LTT) groups that did and
alking speed (10MWT)
LTT
P-value MID achieved MID not achieved P-value
<0.01 16.0 (3.5) 14.4 (1.2) 0.70
0.02 1.1 (0.3) 0.5 (0.1) 0.01
0.02 364.5 (92.8) 171.6 (28.1) 0.02
0.01 12.1 (3.1) 45.1 (9.5) 0.18
0.98 46.6 (7.9) 25.4 (3.9) 0.09
0.94 17.1 (2.7) 11.6 (1.5) 0.16
0.55 48.4 (5.8) 32.9 (3.7) 0.09
0.65 160.7 (30.4) 115.4 (15.9) 0.27
ute walk test (6MWT); timed up and go (TUG); maximum voluntary isometric
M) and peak velocity during isokinetic dorsiflexion (Vp).
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Figure 3 Peak velocity (Vp) during dorsiflexion in the combined locomotor treadmill training (LTT; blue) and Tizanidine (TizLTT; red)
group. (a) Mean (SEM) at 0, 1, 2 and 4 weeks into the intervention and (b) change in Vp plotted against change in walking speed from baseline
to the 4th week assessment, for subjects in the TizLTT group that did (filled diamonds) and did not (open diamonds) achieve the minimal
important difference (MID) in the 10MWT.
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walking speed, supporting our first hypothesis. Improve-
ments in walking speed have been reported previously
after LTT [23,24,30,34,41,42], which have been associ-
ated with improvements in overall muscle strength and
balance [30]. We also noted an associated improvement
in dorsiflexion MVIC, however the change was relatively
small. Our group-averaging analysis revealed that the
addition of Tizanidine, an α2 noradrenergic agonist, to
LTT did not increase or decrease the overall magnitude of
change, as predicted in our second hypothesis. Tizanidine
has been shown to reduce hypertonia in SCI individuals as
assessed by a reduction in passive resistance [14-17], how-
ever its direct benefit on gait outcomes remain ambigu-
ous. Hypertonia results in exaggerated reflex activity aswell as increased intrinsic stiffness in the muscle and sur-
rounding tissue; Tizanidine depresses interneuron excit-
ability [18], thus it attempts to reduce exaggerated reflex
activity (spasticity). This may be inadequate to improve
gait function since it has been proposed that reflex activity
is increased in SCI compared with healthy people only
during passive stretch of muscle [7], although our earlier
study did note increased reflex stiffness in SCI compared
with healthy subjects under active conditions [11].
Alternatively, Tizanidine may enhance gait function in
some but not all SCI individuals. We previously reported
the effects of a similar dose of Tizanidne alone for 4 weeks
on clinical scores, and found that the participants that
attained the minimal important difference (a magnitude
of change that was greater than the variability in the
Duffell et al. Journal of NeuroEngineering and Rehabilitation  (2015) 12:29 Page 8 of 10measurement technique) for both walking speed and en-
durance were higher functioning individuals, evidenced by
significantly higher WISCI II and baseline clinical scores
[34]. Thus, Tizanidine may have facilitated LTT in specific
individuals, resulting in a higher number of individuals
achieving a clinically relevant improvement in function
(the MID for walking speed) than LTT alone, as opposed
to increasing walking speed to a greater overall magnitude
than with LTT alone, as we hypothesized. Indeed, using
MID analysis, our data showed that a higher proportion of
subjects achieved the MID for walking speed in the com-
bined TizLTT group (40%), compared with LTT alone
(13%). This finding supports the notion that Tizanidine
did have a facilitatory effect on LTT, in specific individuals
with SCI.
When comparing those individuals that achieved the
MID for the 10MWT with those that did not, we found
that the individuals that achieved the MID were higher
functioning at baseline, with significantly higher WISCI II
scores and improved baseline scores for all clinical mea-
sures taken (Table 3). This supports our previous findings
[34] that higher functioning individuals may be more
likely to respond to LTT and additionally indicates that
Tizanidine may facilitate LTT specifically for higher func-
tioning individuals, in terms of improving functional cap-
acity during gait.
There were no significant differences in the baseline
measured kinematic and kinetic variables between the
subjects that did and did not achieve the MID for walk-
ing speed, among the TizLTT group (Table 3). Thus,
while baseline functional levels may be predictive of
whether or not Tizanidine would be a beneficial adjunct
to rehabilitative therapies, the specific neuromuscular
properties measured here do not appear to be predictive
of clinical outcomes. There was however a significant
moderate correlation between the change in dorsiflexion
isokinetic peak velocity and change in walking speed for
the subjects in the TizLTT group (r2 = 0.40; P < 0.05). In
addition, peak velocity tended to improve in those that
did achieve the MID for walking speed in the TizLTT
group but not in those that achieved the MID in the
LTT alone group or among the subjects that did not
achieve the MID for both groups (Figure 3a). This result
may indicate that Tizanidine facilitated LTT by restoring
inhibitory mechanisms, which reduced spasticity in plan-
tarflexor muscles. This may have in turn reduced the in-
hibitory effects of plantarflexor muscles on dorsiflexors,
resulting in improved voluntary activation of the ankle
dorsiflexors. After SCI, the inhibitory effects of dorsiflexors
on plantarflexors typically reduce or become facilitatory
[43,44], which can cause co-contraction. Theoretically, res-
toration of inhibitory mechanisms would reverse these
changes, resulting in reduced co-contraction or joint stiff-
ness, allowing greater stretch in the planterflexor musclesto be achieved during LTT [15]. Since our observations of
increased peak velocity were not made during LTT, and in-
hibition was not assessed in this study, these proposed
underlying mechanisms are only speculative, and not fully
supported by the data presented here. Previous studies
have similarly reported improved functional outcomes
from combination therapies compared to LTT therapy pro-
vided alone [24] and conventional physical therapy [33];
the data presented here provide further support for the use
of combinational therapies.
It should be noted that the dose provided in the
present study was relatively low (approx. 8.5 mg/day for
an individual of 70 kg body mass). Knutsson et al. [15]
noted improved voluntary activation (assessed by EMG
activity) in SCI patients following 10 mg/day of Tizani-
dine [15], but improved gait capacity was only noted in
4 patients that were administered a much higher dose of
Tizanidine (32 mg/day). In that study, improved gait
capacity was attributed to lowered passive resistance in
the plantarflexor muscles, thus allowing greater dorsi-
flexion during the swing phase of gait [15]. In the present
study, both LTT and TizLTT were administered over a
relatively short period (4 weeks or 12 LTT sessions). For
LTT, the total number of training sessions required to im-
prove walking outcomes >MID is in the range 10–130
sessions [45]. Therefore, providing a higher dose of Tiza-
nidine, or providing interventions for a longer duration,
may have increased the magnitude of change in walking
speed for the combined intervention compared with LTT
alone. Finally, there was no control group (no interven-
tion) in this study; control data was presented in our pre-
vious publication [34] and can be used as a comparison
with the results presented here.Conclusions
Tizanidine appears to facilitate the effects of LTT on gait
function in higher functioning individuals with SCI. This
was evidenced by improvements in walking speed >MID
for a higher number of individuals in the TizLTT com-
pared with LTT group. The change in walking speed was
associated with the change in isokinetic peak velocity of
dorsiflexion in the TizLTT group, and therefore Tizani-
dine may have facilitated LTT through restoration of in-
hibitory mechanisms, resulting in greater stretch in the
planter flexor muscles during the LTT.
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